USA - New York Stock Exchange - NYSE:LLY - US5324571083 - Common Stock
Taking everything into account, LLY scores 7 out of 10 in our fundamental rating. LLY was compared to 190 industry peers in the Pharmaceuticals industry. LLY scores excellent on profitability, but there are some minor concerns on its financial health. LLY is not overvalued while it is showing excellent growth. This is an interesting combination. LLY also has an excellent dividend rating. These ratings would make LLY suitable for dividend and growth investing!
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.02% | ||
| ROE | 77.38% | ||
| ROIC | 28.84% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.41% | ||
| PM (TTM) | 30.99% | ||
| GM | 83.03% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.72 | ||
| Debt/FCF | 6.6 | ||
| Altman-Z | 8.39 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.24 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.27 | ||
| Fwd PE | 31.38 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 152.68 | ||
| EV/EBITDA | 36.67 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.64% |
ChartMill assigns a fundamental rating of 7 / 10 to LLY.
ChartMill assigns a valuation rating of 5 / 10 to ELI LILLY & CO (LLY). This can be considered as Fairly Valued.
ELI LILLY & CO (LLY) has a profitability rating of 9 / 10.
The Price/Earnings (PE) ratio for ELI LILLY & CO (LLY) is 47.27 and the Price/Book (PB) ratio is 41.3.
The Earnings per Share (EPS) of ELI LILLY & CO (LLY) is expected to grow by 84.93% in the next year.